[{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Yttrium Radioisotopes","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sirtex Medical \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"12","companyTruncated":"Sirtex Medical \/ Grand Pharmaceutical Group Limited"}]

Find Clinical Drug Pipeline Developments & Deals for Yttrium Radioisotopes

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : SIR-Spheres Y-90 resin microspheres is the first therapeutic radiopharmaceutical approved by the NMPA based on clinical trial data, for the treatment of patients with colorectal cancer liver metastases.

                          Brand Name : SIR-Spheres Y-90

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 09, 2022

                          Lead Product(s) : Yttrium Radioisotopes

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Grand Pharmaceutical Group Limited

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank